LALINDEN ADVISORS LP

Institutional investor · Portfolio as of Q2 2024

SEC EDGAR SourceSEC Filings

Top Holdings291 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
??SEA LTDDelisted
288.6M$309.3M2.6%
Decreased
0
??SPOTIFY USA INCDelisted
Bond
301.4M$287.2M2.4%
Increased
83
??CONFLUENT INCDelisted
Bond
321.8M$278.3M2.3%
Increased
64
314.8M$261.3M2.2%
Increased
62
??INSMED INCDelisted
Bond
117.6M$248.7M2.1%
New
80
??MONGODB INCDelisted
Bond
172M$226.5M1.9%
Increased
51
123.2M$217M1.8%
New
70
231.8M$211M1.8%
Increased
55
??SNAP INC
Bond
261.2M$208.6M1.7%
Increased
51
161.6M$208.5M1.7%
Decreased
0
72.8M$207.3M1.7%
Increased
50
??MICROSTRATEGY INCDelisted
Bond
152.8M$183.3M1.5%
New
70
140M$183.2M1.5%
Increased
50
184.4M$180.5M1.5%
Increased
51
??LIVONGO HEALTH INCDelisted
Bond
186.3M$177.4M1.5%
Decreased
0
??SEA LTD
Bond
180.1M$157M1.3%
Increased
60
??ASCENDIS PHARMA ADelisted
Bond
140.2M$156.5M1.3%
Increased
54
70.7M$156.4M1.3%
Increased
60
158.7M$145M1.2%
Increased
52
157.3M$142.1M1.2%
Increased
48
$12B
AUM
291
Positions
Q2 2024
Filing
Rating · 2.0
Quarterly Portfolio Change
+0%Q3'22$10.9B-13%Q4'22$9.5B-0%Q1'23$9.5B+0%Q2'23$9.5B+2%Q3'23$9.7B+8%Q4'23$10.5B
Activity profile
$ moved · Q2'24
New24%Increased22%Decreased29%Exited25%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.8 years
<1Q7%1-4Q20%1-2Y22%2Y+50%

LINDEN ADVISORS LP manages $12B across 291 positions as of Q2 2024. Top holdings: SEA LTD (2.6%), SPOTIFY USA INC (2.4%), CONFLUENT INC (2.3%). Fund DNA: Momentum Trader. HoldingsIntel Rating: 2/5.0.

Q2 2024 Summary

Active quarter - 27 new positions, 51 exits, 73 increased. No standout high-conviction moves this quarter. Portfolio: $12.0B across 291 positions.

Top holdings by portfolio weight

Total AUM$12B
SEA LTD2.58%
SPOTIFY USA 2.40%
CONFLUENT IN2.32%
DRAFTKINGS I2.18%
INSMED INC2.08%
MONGODB INC1.89%
TRANSMEDICS 1.81%
CLOUDFLARE I1.76%
SNAP INC1.74%
SAREPTA THER1.74%
Other1.73%

Portfolio allocation by GICS sector

Sectors6
Utilities47.92%
Unknown23.02%
Technology11.71%
Financial Services11.06%
Basic Materials5.20%
Healthcare1.09%

Behavioral investing profile

Checking access…
Momentum Trader
Compare DNA across all funds
7-dimension quality assessment
Below Average(2.0 / 5.0)
Track Record61
Conviction31
Concentration37
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
8Q
BR10806XAD4BRIDGEBIO PHARMA INC
Q3 2024 Q2 2026+157.4M shares+$200.5M
7Q
VI928298AR9VISHAY INTERTECHNOLOGY INC
Q4 2024 Q2 2026+353.9M shares+$770.5M
4Q
CO19459JAC8COLLEGIUM PHARMACEUTICAL INC
Q3 2025 Q2 2026+26.6M shares+$50.6M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used